DEERFIELD MANAGEMENT COMPANY, L.P.: ZENAS BIOPHARMA INC (UNKNOWN): Quarterly 13F Position History
As of Q2 2026, DEERFIELD MANAGEMENT COMPANY, L.P. reported 1,012,405,000 shares of ZENAS BIOPHARMA INC (UNKNOWN), worth $1.5B and representing 15.2% of its 13F equity book. Quarter-over-quarter share count change: + 1,012,405,000 (re-initiated) . The position first appeared in Q2 2016 and has been disclosed across 41 13F-HR filings in Pactolio's tracked window.
- 1,012,405,000Shares Held (Latest Filing)
- $1.5BReported Market Value (Latest Filing)
- 15.2%Portfolio Weight (% of 13F Equity Book)
- +1,012,405,000Quarter-over-Quarter Share Change
- +$1.5BQuarter-over-Quarter Value Change
- 1,012,405,000Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 41 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 1,012,405,000 | +1,012,405,000 | – | $1.5B | 15.2% | $1.4 |
| Q1 2026 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2025 | 0 | 2,494,108 | -100.0% | $0 | 0.0% | – |
| Q3 2025 | 2,494,108 | 0 | – | $1.3M | 0.0% | $0.5 |
| Q2 2025 | 2,494,108 | 0 | – | $1.1M | 0.0% | $0.5 |
| Q1 2025 | 2,494,108 | +540,336 | +27.7% | $1.4M | 0.0% | $0.6 |
| Q4 2024 | 1,953,772 | 690,774 | -26.1% | $4.5M | 0.1% | $2.3 |
| Q3 2024 | 2,644,546 | +1,741,324 | +192.8% | $5.2M | 0.1% | $2.0 |
| Q2 2024 | 903,222 | 377,050 | -29.5% | $3.2M | 0.1% | $3.5 |
| Q1 2024 | 1,280,272 | +608,272 | +90.5% | $226.8K | 0.0% | $0.2 |
| Q4 2023 | 672,000 | 0 | – | $5.0K | 0.0% | $0.0 |
| Q3 2023 | 672,000 | 2,400,352 | -78.1% | $134.4K | 0.0% | $0.2 |
| Q2 2023 | 3,072,352 | +1,172,959 | +61.8% | $15.8M | 0.3% | $5.1 |
| Q1 2023 | 1,899,393 | 8,213,081 | -81.2% | $3.8M | 0.1% | $2.0 |
| Q4 2022 | 10,112,474 | +1,851,113 | +22.4% | $27.4M | 0.6% | $2.7 |
| Q3 2022 | 8,261,361 | 0 | – | $13.9M | 0.3% | $1.7 |
| Q2 2022 | 8,261,361 | 0 | – | $14.1M | 0.3% | $1.7 |
| Q1 2022 | 8,261,361 | 1,655,795 | -16.7% | $16.0M | 0.4% | $1.9 |
| Q4 2021 | 9,917,156 | 2,239,374 | -18.4% | $74.2M | 1.6% | $7.5 |
| Q3 2021 | 12,156,530 | +1,560,350 | +14.7% | $95.3M | 1.9% | $7.8 |
| Q2 2021 | 10,596,180 | 3,686,900 | -25.8% | $107.2M | 1.9% | $10.1 |
| Q1 2021 | 14,283,080 | 573,333 | -3.9% | $154.0M | 3.2% | $10.8 |
| Q4 2020 | 14,856,413 | 1,832,917 | -11.0% | $275.4M | 5.4% | $18.5 |
| Q3 2020 | 16,689,330 | +5,891,148 | +54.6% | $191.1M | 4.7% | $11.4 |
| Q2 2020 | 10,798,182 | 42,118 | -0.4% | $119.0M | 3.5% | $11.0 |
| Q1 2020 | 10,840,300 | +10,840,300 | – | $103.7M | 3.3% | $9.6 |
| Q4 2019 | 0 | 3,607,643 | -100.0% | $0 | 0.0% | – |
| Q3 2019 | 3,607,643 | 0 | – | $28.3M | 1.2% | $7.9 |
| Q2 2019 | 3,607,643 | 3,970,326 | -52.4% | $36.0M | 1.3% | $10.0 |
| Q1 2019 | 7,577,969 | 6,659,675 | -46.8% | $39.1M | 1.5% | $5.2 |
| Q4 2018 | 14,237,644 | +7,055,671 | +98.2% | $43.3M | 1.8% | $3.0 |
| Q3 2018 | 7,181,973 | 3,950,552 | -35.5% | $57.0M | 2.1% | $7.9 |
| Q2 2018 | 11,132,525 | 679,723 | -5.8% | $71.3M | 2.5% | $6.4 |
| Q1 2018 | 11,812,248 | +7,452,451 | +170.9% | $92.7M | 3.3% | $7.8 |
| Q4 2017 | 4,359,797 | 957,000 | -18.0% | $18.8M | 0.7% | $4.3 |
| Q3 2017 | 5,316,797 | +391,805 | +8.0% | $35.3M | 1.6% | $6.6 |
| Q2 2017 | 4,924,992 | 4,126,925 | -45.6% | $19.4M | 1.1% | $3.9 |
| Q1 2017 | 9,051,917 | 6,993,512 | -43.6% | $35.2M | 1.4% | $3.9 |
| Q4 2016 | 16,045,429 | 435 | -0.0% | $80.0M | 3.3% | $5.0 |
| Q3 2016 | 16,045,864 | 11,428,036 | -41.6% | $96.6M | 4.5% | $6.0 |
| Q2 2016 | 27,473,900 | – | – | $161.9M | 6.4% | $5.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did DEERFIELD MANAGEMENT COMPANY, L.P. first disclose a UNKNOWN position in 13F-HR filings?
DEERFIELD MANAGEMENT COMPANY, L.P. first reported ZENAS BIOPHARMA INC (UNKNOWN) on its 13F-HR filing for the period ending 2016-06-30 (Q2 2016). The position has appeared on 41 reported quarters within Pactolio's tracked window.
What was DEERFIELD MANAGEMENT COMPANY, L.P.'s most recent quarter-over-quarter share-count change in UNKNOWN?
Between Q1 2026 and Q2 2026, DEERFIELD MANAGEMENT COMPANY, L.P. added 1,012,405,000 shares of UNKNOWN (re-initiated), bringing the total reported position to 1,012,405,000 shares at a market value of $1.5B.
Does the implied price-per-share represent DEERFIELD MANAGEMENT COMPANY, L.P.'s cost basis in UNKNOWN?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.